Industry Insights · Device Segments & Clinical
A double breakthrough in minimally invasive glaucoma care: RF ablation and suprachoroidal drainage
Glaucoma is the leading irreversible blinding eye disease, and stable long-term IOP control is almost the only path.
The pain of glaucoma: IOP control is the only path
Glaucoma is the leading irreversible blinding eye disease, and stable long-term IOP control is the only path; but traditional surgery's trauma, complications and uncertain long-term efficacy deter many. More minimally invasive and precise is the global pursuit.
RF ablation: gently 'closing the valve'
Unlike traditional ciliary photocoagulation, RF ablation uses precise electrodes and minimally invasive access to gently modulate the ciliary body to reduce aqueous production while improving circulation via thermal effects — a multi-mechanism approach.
Suprachoroidal drainage: a new 'outlet'
The self-developed suprachoroidal drainage implant opens a new aqueous outflow path, pairing with reduced production for a 'less in + more out' approach. Two first-in-human/China cases mark original technology moving from lab to operating table.
The BIO angle
FAQ
Why control IOP in glaucoma?
It's the leading irreversible blinding eye disease; stable long-term IOP control is the only effective path to slow optic-nerve damage and preserve vision.
How does RF ablation differ from photocoagulation?
Photocoagulation 'just burns'; RF ablation uses precise electrodes to gently reduce aqueous production and improve circulation, pursuing a multi-mechanism, more controllable IOP drop.
What does a suprachoroidal drainage implant do?
It opens a new aqueous outflow path, increasing outflow, paired with production-reducing procedures to lower IOP.
Related reading
- The Century-Long Catheter Infection War: Foley Design, CAUTI and the Coating Path | BIO Insights
- Nystagmus Device Approved: After the Breakthrough, Commercialization Begins | BIO Insights
- AI Medical Devices 2025: a RMB52.5bn Market, Ten Leaders, and Why Materials Still Matter | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.